Abstract
The role of the Th17/interleukin (IL)-23 pathway has been well elucidated in psoriasis. The IL-17 family includes 6 cytokines: IL-17A, IL-17B, IL-17C, IL-17D, IL-17E, and IL-17F. Two monoclonal antibodies targeting IL-17A (secukinumab, ixekizumab) and one antibody against the IL-17 receptor (brodalumab) have been approved for the treatment of moderate-to-severe plaque psoriasis. Clinical efficacy, safety, and tolerability of each agent is reviewed.
©2018 Frontline Medical Communications.
MeSH terms
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Humanized / adverse effects
-
Antibodies, Monoclonal, Humanized / therapeutic use*
-
Dermatologic Agents / adverse effects
-
Dermatologic Agents / therapeutic use*
-
Humans
-
Interleukin-17 / antagonists & inhibitors*
-
Psoriasis / drug therapy*
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Dermatologic Agents
-
Interleukin-17
-
brodalumab
-
ixekizumab
-
secukinumab